![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Summary
The new vasodilating agent prazosin has been used in 14 patients with strictly defined refractory hypertension. In the 10 patients who completed the study there was an average reduction in blood pressure of about 20%. Six of these patients became normotensive. During the study only 1 patient had a reduction in renal function, as measured by endogenous creatinine clearance.
Combination of prazosin with other antihypertensive drugs caused no orthostatic hypotension of practical importance. Side-effects were few and negligible in all patients except in 1 who could not tolerate the drug.